ProKidney (PROK) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed ProKidney (PROK) over the past year, gaining 3.4% versus a loss of 49.1%. Over five years, ZVRA leads with a +12.6% price change compared with -83.2% for PROK. ProKidney is the larger company by market cap ($662.6 million vs $653.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | ZVRA |
|---|---|---|
| Share price | $1.66 | $11.00 |
| Market cap | $662.64M | $653.22M |
| 1-day change | +5.73% | -0.72% |
| YTD return | -25.89% | +22.77% |
| 1-year return | -49.08% | +3.38% |
| 5-year return | -83.18% | +12.59% |
| P/E ratio (TTM) | — | 11.96 |
| Forward P/E | — | 10.22 |
| EPS (TTM) | $-0.55 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.48 | $15.04 |
| 52-week low | $1.30 | $8.01 |
| Distance from 52-week high | -52.30% | -26.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +276.51% | +127.27% |
| Average volume | 1.30M | 1.11M |
| Shares outstanding | 208.93M | 59.38M |
| Employees | 231 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed PROK by 52.5 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
PROK vs ZVRA FAQ
Which is bigger, ProKidney or Zevra Therapeutics?
ProKidney (PROK) is larger, with a market capitalization of $662.64M compared with $653.22M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, PROK or ZVRA?
ZVRA returned +3.38% over the past 12 months, compared with -49.08% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Zevra Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ProKidney and Biotechnology: Pharmaceutical Preparations for Zevra Therapeutics.